Planned Asia-Pacific enrolment for the Phase III DAREON®-NEC-1 trial: first-line (1L) obrixtamig + carboplatin/etoposide (SoC) vs SoC in patients (pts) with delta-like ligand 3 (DLL3)-positive extrapulmonary neuroendocrine carcinoma (epNEC) (ESMO Asia 2026) - Oct 1, 2026 - Abstract #1127TiP; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available
Clinical • P3 data • Endocrine Cancer • Neuroendocrine Carcinoma • Oncology • Solid Tumor • DLL3
|
|
Thomas Boerner; Timon Vandamme; Marianne E. Pavel; Masafumi Ikeda; Thorvardur R. Halfdanarson; Simron Singh; Lin Shen; Sophia Atijeh Valai; Zohreh Schmitz; Zilu Liu; Valeria Lifke; Jaume Capdevila
|